The multidisciplinary research will increase knowledge and improve capabilities for development of new or improved medical countermeasures to chemical and biological threats for both pre-and…

The Defense Threat Reduction Agency awarded Georgia TECH Research Corp $629,668.94 on March 9, 2026, under the Scientific Research - Combating Weapons of Mass Destruction program (CFDA 12.351) to advance medical countermeasures against chemical and biological threats in pre- and post-exposure scenarios. The grant supports multidisciplinary research to develop a threat-agnostic platform for studying respiratory pathogens and discovering, rapidly developing, and producing immune-based medical countermeasures. The award carries a period of performance through March 8, 2031, with place of performance in Atlanta, Georgia. This project grant modification incrementally funds the base line item and incorporates a revised statement of work.

The multidisciplinary research will increase knowledge and improve capabilities for development of new or improved medical countermeasures to chemical and biological threats for both pre-and post-exposure scenarios. This project is poised to deliver a threat-agnostic platform with the potential to revolutionize how respiratory pathogens are studied and how immune-based mcms against such pathogens are discovered, rapidly developed, and produced.